A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
1 other identifier
interventional
645
2 countries
32
Brief Summary
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 16, 2006
CompletedFirst Posted
Study publicly available on registry
February 20, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2006
CompletedDecember 24, 2007
December 1, 2007
February 16, 2006
December 19, 2007
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of plaque psoriasis
You may not qualify if:
- Skin disorder other than plaque psoriasis in the areas to be treated.
- Disease on only elbows, knees, and scalp
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Astellas Pharma Inclead
- Astellas Pharma US, Inc.collaborator
Study Sites (32)
Unknown Facility
Hot Springs, Arkansas, 71913, United States
Unknown Facility
San Diego, California, 92117, United States
Unknown Facility
San Francisco, California, 94118, United States
Unknown Facility
Longmont, Colorado, 80501, United States
Unknown Facility
New Haven, Connecticut, 06511, United States
Unknown Facility
Washington D.C., District of Columbia, 20010, United States
Unknown Facility
Miami, Florida, 33175, United States
Unknown Facility
Newnan, Georgia, 30263, United States
Unknown Facility
Evansville, Indiana, 47713, United States
Unknown Facility
South Bend, Indiana, 46617, United States
Unknown Facility
Iowa City, Iowa, 52242, United States
Unknown Facility
St Louis, Missouri, 63117, United States
Unknown Facility
New York, New York, 10029, United States
Unknown Facility
Rochester, New York, 14623, United States
Unknown Facility
Winston-Salem, North Carolina, 27157, United States
Unknown Facility
Cincinnati, Ohio, 45219, United States
Unknown Facility
Portland, Oregon, 97210, United States
Unknown Facility
Philadelphia, Pennsylvania, 19104, United States
Unknown Facility
Nashville, Tennessee, 37203, United States
Unknown Facility
Bryan, Texas, 77802, United States
Unknown Facility
Dallas, Texas, 75230, United States
Unknown Facility
Galveston, Texas, 77555, United States
Unknown Facility
Burlington, Vermont, 05401, United States
Unknown Facility
Lynchburg, Virginia, 24501, United States
Unknown Facility
Dayton, Washington, 99328, United States
Unknown Facility
Madison, Wisconsin, 53719, United States
Unknown Facility
Winnipeg, Manitoba, R3C 0N2, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, A1B 4S8, Canada
Unknown Facility
North Bay, Ontario, P1B 3Z7, Canada
Unknown Facility
Waterloo, Ontario, N2J 1C4, Canada
Unknown Facility
Windsor, Ontario, N8W 1E6, Canada
Unknown Facility
Saskatoon, Saskatchewan, S7N 0W8, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
J Rico, MD
Astellas Pharma US, Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
February 16, 2006
First Posted
February 20, 2006
Study Completion
November 1, 2006
Last Updated
December 24, 2007
Record last verified: 2007-12